Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ASCO 2020 Data Drive New Discussions in NSCLC

August 10th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in non–small cell lung cancer .

Optimizing Testing Strategies in Non–Small Cell Lung Cancer

August 10th 2020

NTRK Fusions in Non–Small Cell Lung Cancer

August 10th 2020

MET Exon 14 Mutations in Non–Small Cell Lung Cancer

August 10th 2020

RET Fusions in Non–Small Cell Lung Cancer

August 10th 2020

ROS1-Rearranged Non–Small Cell Lung Cancer

August 10th 2020

Rebiopsy at Progression of ALK-Rearranged NSCLC

August 10th 2020

Treating ALK-Rearranged Non–Small Cell Lung Cancer

August 10th 2020

Trials in ALK-Rearranged Non–Small Cell Lung Cancer

August 10th 2020

KRAS Testing in Non¬–Small Cell Lung Cancer

August 10th 2020

Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer

August 10th 2020

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 Insertion

August 10th 2020

EGFR Exon 20 Mutations in Non–Small Cell Lung Cancer

August 10th 2020

Chemotherapy-TKI Combinations in Metastatic EGFR+ Lung Cancer

August 10th 2020

TKI Combinations in Metastatic EGFR+ Lung Cancer

August 10th 2020

Role of Adjuvant Osimertinib in Early Stage NSCLC

August 10th 2020

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

August 10th 2020

CS1001 Plus Chemotherapy Shows Significant PFS Prolongation in Stage IV NSCLC

August 10th 2020

The anti–PD-L1 monoclonal antibody CS1001 in combination with platinum-based chemotherapy led to a significant improvement in progression-free survival when used as a frontline treatment for patients with stage IV squamous and nonsquamous non–small cell lung cancer.

ADCs Are Poised to Enter HER2-Mutant NSCLC Armamentarium

August 10th 2020

Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.

Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma

August 9th 2020

Nivolumab plus ipilimumab significantly improved overall survival versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma.